The efficacy of alfuzosin and solifenacin combination in BPH patients with overactive bladder and low flowrate
Abstract
Introduction. The alfuzosin and solifenacin combination has previously demonstrated high efficacy and safety in patients with BPH and overactive bladder (OAB), including with severe LUTS, if cases of mechanical type of bladder outlet obstruction (BOO) were excluded. The present study aim was to confirm the efficacy and safety of such combination therapy in patients with severe urinary disorders according to uroflowmetry (UFM).
Materials and methods. The observational multicenter AVIATOR study included 208 men with BPH and OAB. Its unique features were: the use of alfuzosin (Alfuprost® MR, 10 mg/day) and solifenacin (Vesigamp, 5 mg/day) combination for 3 months in patients with moderate to severe LUTS; intravesical prostatic protrusion ≥ 10 mm as exclusion criteria; comprehensive assessment of symptoms dynamics by IPSS/QoL, OABSS, PPIUS questionnaires; initial stratification of patients subgroups by Qmax; assessment of changes by UFM report and curve; evaluation of treatment efficacy by «clinically significant response» achieving.
Results. Initially, patients were divided into two subgroups, depending on Qmax index: PG1 with Qmax 25% in 87.2% and 90.6% versus 98.0% and 100.0%; Qmax increased for > 30% in 55.9% and 15.1% versus 92.2% and 50.0%, due to a different «starting base» and achievement of normal Qmax values in PG2 after only one month of treatment. The combined treatment has demonstrated a high safety level.
Conclusion. The study showed high efficacy and safety of…
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.